Bullish & Foolish
Full GUTS fundamentals All 466 on the Survival Watch

GUTSFractyl Health, Inc.

Is Fractyl Health struggling financially?

Yes, by its own account. Fractyl Health told the SEC on 12 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Cries for help

  • Restructuring

    As part of the Strategic Reprioritization, we announced that we streamlined resources, including a workforce reduction impacting 22 employees.

    Form 10-K, filed 24 Mar 2026. Read it on SEC.gov

Signs of a way out

Nothing in the filings we have read names a way out.

Sector
Biotech/Pharma
Market cap
$124.2M
Source filing
10-Q 12 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 5months

    If the burn speeds up

    Empty by Nov 2026

  • 8months

    If it eases off

    Empty by Mar 2027

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$47.1M

÷

Cash burned over the last 12 months

$90.9M

What Fractyl Health told the SEC

…that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Generally, to be considered probable of being effectively implemented, the plans must have been approved by the…

Fractyl Health, Inc., Form 10-Q, filed 12 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 223.9% share-count increase The company issued stock. Each share now owns 69.1% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 35% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt